企業概要
Sotera Health Company is a prominent entity within the healthcare sector, specifically focusing on the diagnostics and research industry by providing sterilization solutions, laboratory testing, and advisory services across the United States, Canada, Europe, and international markets. Operating through three distinct segments including Sterigenics, Nordion, and Nelson Labs, the firm delivers outsourced services that support critical healthcare infrastructure and research initiatives globally. As of the latest data, the company holds a substantial market capitalization of 43.3 億ドル（$4.33B）and generates annual revenues reaching 11.6 億ドル（$1.16B）, supported by an organizational workforce of approximately 3,000 名（3000）employees. These valuation metrics and revenue figures position Sotera Health Company as a significant player in the global healthcare supply chain, reflecting a mature operational scale that spans multiple geographical regions and specialized service lines essential for modern medical diagnostics and sterilization processes.
財務健全性
The company reported trailing twelve-month (TTM) revenues of 11.6 億ドル（$1.16B）with a corresponding net income of 7794 万ドル（$77.94M）and EBITDA standing at 5.5336 億ドル（$553.36M）, indicating a substantial gap between gross revenue and net profit that highlights significant operational expenses and cost structures inherent in its service-based business model. This business generates robust free cash flow of 2.368 億ドル（$236.80M）, which provides the firm with considerable financial flexibility to manage capital expenditures, service its debt obligations, or pursue strategic initiatives without relying solely on external financing. The company's profitability structure is characterized by a gross margin of 55.5%, an operating margin of 35.8%, and a profit margin of 6.7%, where the high gross margin suggests efficient production or service delivery costs, while the lower profit margin reflects the impact of significant operating expenses and other deductions on the bottom line. Regarding leverage, the firm maintains a cash balance of 3.449 億ドル（$344.90M）against a total debt load of 22.8 億ドル（$2.28B）, resulting in a debt-to-equity ratio of 375.56, which indicates a highly leveraged balance sheet where interest payments and principal repayments constitute a major portion of financial obligations. Despite this leverage, the current ratio of 2.46 suggests a strong short-term liquidity position, as the company holds more than double the current assets necessary to cover its short-term liabilities. Furthermore, the return on equity (ROE) of 15.4% and return on assets (ROA) of 8.2% demonstrate that management is utilizing the company's equity and asset base to generate returns, though the high debt levels necessitate careful monitoring of interest rate sensitivity and cash flow coverage.
バリュエーション評価
Valuation metrics for Sotera Health Company reveal a trailing P/E ratio of 56.44 compared to a forward P/E of 14.56, a stark disparity that implies the market expects a significant and rapid increase in future earnings to justify the current stock price relative to anticipated performance. The price-to-book ratio stands at 7.15, indicating that the market values the company at a substantial premium over its book value, reflecting high growth expectations or intangible asset valuations such as intellectual property and brand strength within the diagnostics sector. Alternative valuation measures include a price-to-sales ratio of 3.72 and an EV/EBITDA multiple of 11.32, which suggest that investors are willing to pay a premium for revenue growth and earnings potential despite the high debt levels inherent in the capital structure. In terms of price volatility, the stock has traded between a 52-week low of 9.53 ドル（$9.53）and a 52-week high of 19.85 ドル（$19.85）, with the current trading price positioned significantly below the recent highs, suggesting a correction from peak valuations or a pullback in investor sentiment. Additionally, the beta value of 1.88 indicates that the stock exhibits high price volatility relative to the broader market, moving nearly twice as much as the benchmark index during periods of market fluctuation.
Growth & Income
Sotera Health Company demonstrated a year-over-year revenue growth rate of 4.6% and an earnings growth rate of 175.4%, illustrating that earnings are expanding at a pace vastly superior to revenue, which implies significant operational leverage or one-time gains contributing to the bottom line. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, signifying that the firm retains all generated earnings to fund internal growth initiatives, debt reduction, or share buybacks rather than distributing cash to shareholders. This strategy of reinvestment is consistent with a capital-intensive growth phase where retaining capital is prioritized over providing immediate income to investors. Overall, the company's profile is defined by moderate revenue expansion coupled with explosive earnings growth, driven by a capital-efficient operating model that leverages its existing asset base to generate disproportionate profit increases.